CJ-30056

AssetAlso atorvastatin/metformin XR 20/500mg

Fixed-dose combination of atorvastatin (HMG-CoA reductase inhibitor) and metformin for metabolic control.

Stage: Phase 3
Modality: Small molecule
Target: AMPK signalling; 2
Indications: 556
Trials: 1
Developer

Indications

2

Hyperlipidemia
Phase 3, Unknown, NCT03639480, clinicaltrials.gov, 7 Oct 2026
Hypertension
Phase 3, Unknown, NCT03639480, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Trials556
Evidence for its targets4
Competitors12
Aging relevance1
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 4 sources